Kintor Pharmaceutical Limited

OTCPK:KNTP.F Stock Report

Market Cap: US$59.5m

Kintor Pharmaceutical Valuation

Is KNTP.F undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of KNTP.F when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: KNTP.F ($0.16) is trading below our estimate of fair value ($15.54)

Significantly Below Fair Value: KNTP.F is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for KNTP.F?

Key metric: As KNTP.F is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for KNTP.F. This is calculated by dividing KNTP.F's market cap by their current book value.
What is KNTP.F's PB Ratio?
PB Ratio1.1x
BookCN¥391.58m
Market CapCN¥431.21m

Price to Book Ratio vs Peers

How does KNTP.F's PB Ratio compare to its peers?

The above table shows the PB ratio for KNTP.F vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average2.8x
ACET Adicet Bio
0.4x6.7%US$74.2m
FIXX Homology Medicines
0.7xn/aUS$54.3m
ENTX Entera Bio
9.1x-100.3%US$58.6m
ATNM Actinium Pharmaceuticals
1.2x2.3%US$45.2m
KNTP.F Kintor Pharmaceutical
1.1x25.8%US$467.6m

Price-To-Book vs Peers: KNTP.F is good value based on its Price-To-Book Ratio (1.1x) compared to the peer average (2.9x).

Price to Book Ratio vs Industry

How does KNTP.F's PB Ratio compare vs other companies in the US Biotechs Industry?

61 CompaniesPrice / BookEstimated GrowthMarket Cap
GRAL GRAIL
0.2x35.7%US$554.58m
IMAB I-Mab
0.4x1.8%US$76.59m
ACET Adicet Bio
0.4x6.7%US$74.16m
MGX Metagenomi
0.3x-23.2%US$70.73m
KNTP.F 1.1xIndustry Avg. 1.9xNo. of Companies81PB01.63.24.86.48+
61 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: KNTP.F is good value based on its Price-To-Book Ratio (1.1x) compared to the US Biotechs industry average (1.8x).

Price to Book Ratio vs Fair Ratio

What is KNTP.F's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

KNTP.F PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio1.1x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate KNTP.F's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Spectrum Pharmaceuticals

US$209.9m

Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology drug products.

SPPI

US$1.03

7D

5.3%

1Y

17.0%

IQVIA Holdings

US$36.6b

Engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific.

IQV

US$201.82

7D

4.7%

1Y

-4.8%

Collegium Pharmaceutical

US$966.2m

A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.

COLL

US$29.96

7D

1.3%

1Y

15.1%